Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
April 14, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
April 04, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
March 22, 2023 08:30 ET
|
Inozyme Pharma Inc.
- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track...
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
February 16, 2023 07:30 ET
|
Inozyme Pharma Inc.
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
February 06, 2023 07:30 ET
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) – BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
January 09, 2023 08:30 ET
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 – - Significant clinical and scientific...
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
December 05, 2022 08:30 ET
|
Inozyme Pharma Inc.
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient...
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
December 01, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...